Stocktoria
GILEAD SCIENCES, INC. GILD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-01-22
GILEAD SCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B |
| SG&A expense | $5.8B | $6.1B | $6.1B | $5.7B | $5.2B |
| Operating income | $10.0B | $1.7B | $7.6B | $7.3B | $9.9B |
| Interest expense | — | — | $944.0M | $935.0M | $1.0B |
| Income tax | $1.3B | $211.0M | $1.2B | $1.2B | $2.1B |
| Net income | $8.5B | $480.0M | $5.7B | $4.6B | $6.2B |
| EPS (diluted) | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
| Operating cash flow | $10.0B | $10.8B | $8.0B | $9.1B | $11.4B |
| Free cash flow | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B |
| Cash & equivalents | — | — | — | $5.4B | $5.3B |
| Inventory | $1.8B | $1.7B | $1.8B | $1.5B | $1.6B |
| Total assets | $59.0B | $59.0B | $62.1B | $63.2B | $68.0B |
| Shareholders' equity | $22.7B | $19.3B | $22.8B | $21.2B | $21.1B |
Source: SEC EDGAR filings · CIK 0000882095 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.